Highlights CKD Corporation

Equities

6407

JP3346800000

Delayed Japan Exchange Other stock markets 02:00:00 2024-05-15 EDT			5-day change	1st Jan Change
3,175 ^JPY	-2.01%		+4.27%	+25.00%

05-13	Jefferies Adjusts CKD'S Price Target to 3,700 Yen From 4,000 Yen, Keeps at Buy	MT
04-15	AstraZeneca: expects a sharp rise in kidney disease	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AstraZeneca: expects a sharp rise in kidney disease	04-15	CF
TVS Supply Chain's Supply of CKD Kits to TVS Motor Crosses 500,000	04-11	MT
Final dividend	03-27	FA
Novo Nordisk: EU could authorize Wegovy by April	02-23	CF
Novo Nordisk: EU authorization for Wegovy by April?	02-23	CF
Disc Medicine Says FDA Grants Fast Track Designation for Investigational Treatment of Chronic Kidney Disease, Anemia	02-20	MT
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD	01-31	MT
FDA Adds 'Boxed Warning' for Hypocalcemia Risk to Amgen's Osteoporosis Drug Prolia	01-19	MT
FDA Adds 'Boxed Warning' for Hypocalcemia Risk to Amgen's Osteoporosis Drug Prolia	01-19	MT
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease	01-03	MT
Hansoh Pharma's Three Drugs Added to China’s National Reimbursement Drug List	12-14	MT
AstraZeneca discontinues two phase III evidence trials for Lokelma	12-01	AN
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast	11-30	MT
Chong Kun Dang Pharmaceutical Inks Largest-Ever Technology Transfer Agreement with Novartis	11-08	MT
US FDA approves Ardelyx's kidney disease-related drug	23-10-17	RE
Novo Nordisk in $1.3 bln deal to buy hypertension drug	23-10-16	RE
Ex-dividend day for interim dividend	23-09-27	FA
Eli Lilly, Boehringer Ingelheim Say US FDA Approved Jardiance Tablets to Treat Adults With Chronic Kidney Disease	23-09-22	MT
Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH	23-09-06	MT
Renalytix hails KidneyIntelX inclusion in guidance to evaluate CKD	23-08-21	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CKD Corporation

Equities

6407

JP3346800000

Highlights

Filters